| Gene symbol | CTAG1B | Synonyms | CT6.1, CTAG, CTAG1, ESO1, LAGE-2, LAGE2B, NY-ESO-1 | Type of gene | protein-coding |
| Chromosome | X | Map location | Xq28 | dbXrefs | |
| Description | cancer/testis antigen 1B | ||||
| Gene symbol | MAGEA3 | Synonyms | CT1.3, HIP8, HYPD, MAGE3, MAGEA6 | Type of gene | protein-coding |
| Chromosome | X | Map location | Xq28 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | MAGE family member A3 | ||||
| Gene symbol | TPTE | Synonyms | CT44, PTEN2, TPTE1 | Type of gene | protein-coding |
| Chromosome | 21 | Map location | 21p11.2 | dbXrefs | |
| Description | transmembrane phosphatase with tensin homology | ||||
| Gene symbol | TYR | Synonyms | ATN, CMM8, OCA1, OCA1A, OCAIA, SHEP3 | Type of gene | protein-coding |
| Chromosome | 11 | Map location | 11q14.3 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | tyrosinase | ||||
| GTO ID | GTC2437 |
| Trial ID | NCT04526899 |
| Disease | Melanoma |
| Altered gene | CTAG1B|TYR|MAGE-A3|TPTE |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | BNT111 |
| Co-treatment | cemiplimab |
| Phase | Phase2 |
| Recruitment status | Active, Not Recruiting |
| Title | Open-label, Randomized Phase II Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma |
| Year | 2021 |
| Country | Australia|Germany|Italy|Poland|Spain|United Kingdom|United States |
| Company sponsor | BioNTech SE |
| Other ID(s) | BNT111-01|2020-002195-12 |
| Vector information | |||
|
|||
| Cohort1: BNT111_cemiplimab | |||||||
|
|||||||
| Cohort2: BNT111 | |||||||
|
|||||||
| Cohort3: cemiplimab | |||||||
|
|||||||